drugset
drugset / Trial / NCT05028127

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

NCT05028127 ↗

Phase 1 Completed 12 enrolled UCB Celltech
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of the study to determine the relative bioavailability of bimekizumab in healthy subjects

Timeline

Start
2016-03-04
Primary completion
2016-06-17
Completion
2016-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimekizumab Monoclonal antibody 160 mg Subcutaneous

Indications

No indication recorded.